OPTIMIZATION OF TREATMENT AND PROGNOSTIC APPROACHES TO BENIGN PROSTATIC HYPERPLASIA COMPLICATIONS
Abstract
The problem of treatment for benign prostatic hyperplasia (BHP) remains highly relevant due to the high prevalence of this disease, its negative impact on the quality of life, and high risk of serious complications, such as acute urinary retention, acute renal failure, hematuria, and bladder tamponade.
Moreover, patients with BHP usually demonstrate high hospitalized incidence. In Nizhny Novgorod region, the hospitalized incidence was 462.3 per 100,000 men of the relevant age in 2010. The majority of BHP patients admitted to hospitals (87.1%) have undergone surgical treatment. More than half of them had emergency hospitalization; 4.6% of patients suffered from acute urinary retention and 1.2% of patients were diagnosed with acute renal failure.
About the Authors
S. M. Pikalov
State Budgetary Healthcare Institution ‘V.D. Seredavin Samara Regional Clinical Hospital’
Russian Federation
Samara
Russian Federation
Samara
D. O. Gusev
State Budgetary Healthcare Institution ‘Samara City Clinical Hospital No. 8’
Russian Federation
Samara
Russian Federation
Samara
A. D. Adilov
State Budgetary Healthcare Institution ‘Orenburg City Clinical Hospital No. 1’
Russian Federation
Orenburg
Russian Federation
Orenburg
A. A. Zimichev
Federal State Budgetary Institution of Higher Education ‘Samara State Medical University’ Ministry of Health of the Russian Federation
Russian Federation
Samara
Russian Federation
Samara
M. S. Klimentyeva
State Budgetary Healthcare Institution ‘Medical and Sanitary Unit No. 5’
Russian Federation
Samara
Russian Federation
Samara
P. V. Sumskiy
State Budgetary Healthcare Institution ‘Orenburg City Clinical Hospital No. 1’
Russian Federation
Orenburg
Russian Federation
Orenburg
I. V. Tarasov
State Budgetary Healthcare Institution ‘Samara City Clinical Hospital No. 8’
Russian Federation
Samara
Russian Federation
Samara
References
1. Zimichev A.A. Sovershenstvovanie urologicheskih i onkologicheskih metodov profilaktiki i lecheniya raka mochevogo puzyrya: dis. ... dokt. med. nauk. – Moskva, 2015. – 272 s.
2. Klinicheskie rekomendacii. Dobrokachestvennaya giperplaziya predstatel'noj zhelezy. God utverzhde-niya: 2019.
3. Ahyai SA, Gilling P, Kaplan SA et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010; 58(3): 384-97.
4. Checcucci E, Autorino R, Cacciamani GE et al.; Uro-technology and SoMe Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Artificial intelligence and neural networks in urology: current clinical applications. Minerva Urol Nefrol. 2019 Dec 12. doi: 10.23736/S0393-2249.19.03613-0.
5. Deng Z, Sun M, Zhu Y et al. Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis. World J Urol. 2018; 36(9): 1355-1364.
6. Frankish K, Ramsey WM (eds). Introduction. The Cambridge handbook of artifcial intelligence. Cambridge Uni-versity Press, Cambridge, 2014. pp 1–14.
7. Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol. 2019; 16(7): 391-403.
8. Good D.W. et al. Prostate Benign Prostatic Hyperplasia // Blandy's Urology. 2019. P. 531-561.
9. Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017; 69S: S36-S40.
10. Han SH, Kim KW, Kim S, Youn YC. Artificial Neural Network: Understanding the Basic Concepts without Mathe-matics. Dement Neurocogn Disord. 2018; 17(3):83-89.
11. He J, Baxter SL, Xu J et al. The practical implementation of artificial intelligence technologies in medicine. Nat Med. 2019; 25(1): 30-36.
12. Huang SW, Tsai CY, Tseng CS et al. Comparative efficacy and safety of new surgical treatments for benign prostat-ic hyperplasia: systematic review and network meta-analysis. BMJ. 2019; 367: l5919.
13. Ichihara K, Masumori N, Fukuta F et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015; 193(3): 921-6.
14. Inzunza G, Rada G, Majerson A. Bipolar or monopolar transurethral resection for benign prostatic hyperplasia? Medwave. 2018; 18(1): e7134.
15. Iscaife A, Dos Anjos G, Barbosa C Neto et al. The role of bladder diverticula in the prevalence of acute urinary re-tention in patients with BPH who are candidates to surgery. Int Braz J Urol. 2018; 44(4): 765-770.
16. Izard J, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int 2011; 108: 89–93.
17. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. Journal of Urology. 1997; 158(2): 481–487.
18. Jiang YL, Qian LJ. Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. BMC Urol. 2019; 19(1): 11.
19. Kaplan SA, Lee JY, Meehan AG, Kusek JW; MTOPS Research Group. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011; 185(4):1369-73.
20. Karavitakis M, Kyriazis I, Omar MI et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol. 2019; 75(5): 788-798.
21. Kenny AG, Pellerin O, Amouyal G et al. Prostate Artery Embolization in Patients With Acute Urinary Retention. Am J Med. 2019;132(11):e786-e790.
22. Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018; 5(1): 28-32.
23. Kim JH, Baek MJ, Sun HY et al. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. PLoS One. 2018; 13(10): e0203479.
24. Lourenco T, Shaw M, Fraser C et al. The clinical effectiveness of transurethral incision of the prostate: a systemat-ic review of randomised controlled trials. World J Urol. 2010; 28(1): 23-32.
25. Malling B, Røder MA, Brasso K et al. Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Radiol. 2019; 29(1): 287-298.
26. Mayer EK, Kroeze SG, Chopra S et al. Examining the 'gold standard': a comparative critical analysis of three con-secutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int. 2012; 110(11): 1595-601.
27. McBee MP, Awan OA, Colucci AT et al. Deep Learning in Radiology. Acad Radiol. 2018; 25(11): 1472-1480.
28. Mónica FZ, De Nucci G. Tadalafil for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2019; 20(8): 929-937.
29. Oelke M, Höfner K, Jonas U et al. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol. 2007; 52(3): 827-34.
30. Ramesh AN, Kambhampati C, Monson JR, Drew PJ. Artificial intelligence in medicine. Ann R Coll Surg Engl. 2004; 86(5): 334-8.
31. Ren RM, Kou M, Lan XX. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis. Chin Med J (Engl). 2010; 123(2): 234-8.
32. Renganathan V. Overview of artificial neural network models in the biomedical domain. Bratisl Lek Listy. 2019; 120(7): 536-540.
33. Roehrborn CG, Siami P, Barkin J et al. CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123-31.
34. Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol 2001; 3(4): 187–192
35. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyper-plasia. Urology. 1994; 43: 284–294.
36. Stuart R, Norvig P (eds) Artifcial intelligence – a modern approach, 3rd edn. Prentice Hall, Upper Saddle River, 2010.
37. Suarez-Ibarrola R, Hein S, Reis G, Gratzke C, Miernik A. Current and future applications of machine and deep learn-ing in urology: a review of the literature on urolithiasis, renal cell carcinoma, and bladder and prostate cancer. World J Urol. 2019 Nov 5. doi: 10.1007/s00345-019-03000-5.
38. Sun F, Sun X, Shi Q, Zhai Y. Transurethral procedures in the treatment of benign prostatic hyperplasia: A systemat-ic review and meta-analysis of effectiveness and complications. Medicine (Baltimore). 2018; 97(51): e13360.
39. Tran BX, Vu GT, Ha GH et al. Global Evolution of Research in Artificial Intelligence in Health and Medicine: A Bib-liometric Study. J Clin Med. 2019 Mar 14;8(3). pii: E360.
40. Ugare UG, Bassey IA, Udosen EJ et al. Management of lower urinary retention in a limited resource setting. Ethiop J Health Sci 2014; 24(4): 329–336.
41. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Geron-tol. 2005; 40(3): 121–8.
42. Wainberg M, Merico D, Delong A, Frey BJ. Deep learning in biomedicine. Nat Biotechnol. 2018; 36(9): 829-838.
43. Wang Y, Bao Y, Liu J et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dys-function: A Systematic Review and Meta-analysis. Low Urin Tract Symptoms. 2018; 10(1): 84-92.
44. Yuan JQ, Mao C, Wong SY et al. Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis. Medicine (Baltimore). 2015; 94(27): e974.
45. Zattoni F, Ficarra V, Novara G. Risk stratification for benign prostatic hyperplasia. Urologia. 2017; 84(3): 153-157.
46. Zhang J, Li X, Yang B et al. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and metaanalysis. World J Urol. 2019; 37(1): 143-153.
47. Zhou Z, Cui Y, Wu J et al. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. 2019; 19(1): 17.
Review
For citations:
Pikalov S.M., Gusev D.O., Adilov A.D., Zimichev A.A., Klimentyeva M.S., Sumskiy P.V., Tarasov I.V. OPTIMIZATION OF TREATMENT AND PROGNOSTIC APPROACHES TO BENIGN PROSTATIC HYPERPLASIA COMPLICATIONS. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2020;(2):40-50. (In Russ.)
Views:
252
Email this article 